Alysa Walker, Ph.D.
Affiliations: | 2010 | University of Washington, Seattle, Seattle, WA |
Area:
Pharmacy, Pharmacology, Molecular BiologyGoogle:
"Alysa Walker"Parents
Sign in to add mentorNina Isoherranen | grad student | 2010 | University of Washington | |
(Changes in hepatic drug metabolizing enzymes during pregnancy.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Kharasch ED, Bedynek PS, Hoffer C, et al. (2012) Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology. 116: 432-47 |
Walker AA, Leslie D, Isoherranen N. (2011) Pregnancy decreases rat CYP1A2 activity and expression Drug Metabolism and Disposition. 39: 4-7 |
Kharasch ED, Walker A, Whittington D, et al. (2009) Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug and Alcohol Dependence. 101: 158-68 |
Kharasch ED, Hoffer C, Whittington D, et al. (2009) Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir. Anesthesiology. 110: 660-72 |
Kharasch ED, Bedynek PS, Walker A, et al. (2008) Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clinical Pharmacology and Therapeutics. 84: 506-12 |
Kharasch ED, Bedynek PS, Park S, et al. (2008) Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clinical Pharmacology and Therapeutics. 84: 497-505 |
Kharasch ED, Walker A, Isoherranen N, et al. (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clinical Pharmacology and Therapeutics. 82: 410-26 |
Kharasch ED, Walker A, Hoffer C, et al. (2005) Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. Journal of Clinical Pharmacology. 45: 1187-97 |
Kharasch ED, Walker A, Hoffer C, et al. (2005) Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. Journal of Clinical Pharmacology. 45: 79-88 |
Kharasch ED, Walker A, Hoffer C, et al. (2004) Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clinical Pharmacology and Therapeutics. 76: 452-66 |